LUMO vs. EQ, ONCY, ASMB, MIST, BRNS, SPRO, PYRGF, EPRX, CUE, and ACRS
Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Equillium (EQ), Oncolytics Biotech (ONCY), Assembly Biosciences (ASMB), Milestone Pharmaceuticals (MIST), Barinthus Biotherapeutics (BRNS), Spero Therapeutics (SPRO), PyroGenesis Canada (PYRGF), Eupraxia Pharmaceuticals (EPRX), Cue Biopharma (CUE), and Aclaris Therapeutics (ACRS). These companies are all part of the "pharmaceutical preparations" industry.
Equillium (NASDAQ:EQ) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, community ranking, valuation, media sentiment, analyst recommendations and risk.
Equillium has a net margin of -32.01% compared to Equillium's net margin of -2,434.69%. Lumos Pharma's return on equity of -51.20% beat Equillium's return on equity.
In the previous week, Equillium had 4 more articles in the media than Lumos Pharma. MarketBeat recorded 4 mentions for Equillium and 0 mentions for Lumos Pharma. Lumos Pharma's average media sentiment score of 0.15 beat Equillium's score of 0.00 indicating that Equillium is being referred to more favorably in the media.
Equillium has higher revenue and earnings than Lumos Pharma. Equillium is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.
27.1% of Equillium shares are owned by institutional investors. Comparatively, 34.0% of Lumos Pharma shares are owned by institutional investors. 30.3% of Equillium shares are owned by company insiders. Comparatively, 25.4% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Equillium received 1 more outperform votes than Lumos Pharma when rated by MarketBeat users. Likewise, 83.33% of users gave Equillium an outperform vote while only 77.27% of users gave Lumos Pharma an outperform vote.
Equillium has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Equillium currently has a consensus target price of $3.90, suggesting a potential upside of 386.89%. Lumos Pharma has a consensus target price of $18.00, suggesting a potential upside of 625.81%. Given Equillium's higher probable upside, analysts clearly believe Lumos Pharma is more favorable than Equillium.
Summary
Equillium beats Lumos Pharma on 12 of the 17 factors compared between the two stocks.
Get Lumos Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lumos Pharma Competitors List
Related Companies and Tools
